The primary strength of this study is its demonstration that TSP2 at SVR12, a marker previously studied in liver disease and targeted for fibrosis treatment, may represent a predictive indicator for the future occurrence of HCC in DAA‐treated hepatitis C patients. This evidence concerns the gene THBS2 and hepatitis C virus infection.